TABLE 1.
Demographic, Clinical, and Reproductive Aging Characteristics of HIV-infected and Non-HIV-infected Women
| Non-HIV (N=25) | HIV (N=49) | P values | |
|---|---|---|---|
| DEMOGRAPHICS AND TRADITIONAL CV RISK PARAMETERS | |||
|
| |||
| Race/Ethnicity | 0.85 | ||
| White | 28% (7/25) | 27% (13/49) | |
| Black/African-American | 64% (16/25) | 59% (29/49) | |
| Hispanic | 4% (1/25) | 8% (4/49) | |
| Other | 4% (1/25) | 6% (3/49) | |
| Age (years) | 47 (46, 51) | 47 (44, 53) | 1.0 |
| Current Statin Use | 4% (1/25) | 8% (4/49) | 0.48 |
| Current HTN | 24% (6/25) | 12% (6/49) | 0.20 |
| Current DM | 16% (4/25) | 12% (6/49) | 0.66 |
| Current Smoking | 56% (14/25) | 47% (23/49) | 0.46 |
| Total Cholesterol (mmol/L) | 4.7 ± 0.7 | 4.9 ± 1.1 | 0.53 |
| LDL Cholesterol (mmol/L) | 2.6 ± 0.7 | 2.8 ± 1.0 | 0.44 |
| HDL Cholesterol (mmol/L) | 1.6 ± 0.5 | 1.6 ± 0.5 | 0.87 |
| Triglycerides (mmol/L) | 0.9 (0.7, 1.4) | 1.0 (0.8, 1.3) | 0.62 |
| SBP (mm Hg) | 122 ± 17 | 114 ± 13 | 0.04 |
| Current IVDU | 4% (1/25) | 2% (1/49) | 0.63 |
| Active Cocaine Use | 0% (0/25) | 10% (5/49) | 0.04 |
| Creatinine (μmol/L) | 71 (62, 71) | 71 (62, 80) | 0.12 |
| BMI (kg/m2) | 29 ± 5 | 28 ± 5 | 0.42 |
| WHR (iliac waist) | 0.91 ± 0.07 | 0.91 ± 0.06 | 0.74 |
| Framingham Point Score | 11 ± 5 | 10 ± 5 | 0.86 |
| ASCVD Risk Score (%)* | 2.0 (0.8, 4.4) | 1.4 (0.8, 3.0) | 0.40 |
| HCV Co-Infection | 20% (5/25) | 31% (15/49) | 0.32 |
|
| |||
| HIV-SPECIFIC PARAMETERS | |||
|
| |||
| Years Since HIV | 15 ± 6 | ||
| Currently on ART | 98% (48/49) | ||
| Duration ART (years) | 8 ± 5 | ||
| Current PI | 59% (29/49) | ||
| Duration PI (years) | 2 (0, 8) | ||
| Current NRTI | 90% (44/49) | ||
| Duration NRTI (years) | 7 ± 5 | ||
| Current NNRTI | 18% (9/49) | ||
| Duration NNRTI (years) | 0 (0, 2) | ||
| CD4 Count (cells/mm3) | 518 (405, 712) | ||
| Nadir CD4 (cells/mm3) | 198 (57, 250) | ||
| Log VL (copies/mL) | 4.1 ± 0.9 | ||
| VL Undetectable | 83% (38/46) | ||
|
| |||
| HORMONAL PARAMETERS | |||
|
| |||
| Estradiol (pmol/L) | 132 (29, 367) | 77 (22, 246) | 0.37 |
| FSH (mIU/mL) | 21 (7, 47) | 45 (8, 68) | 0.22 |
| AMH (ng/mL) | <0.023 (<0.023, 0.53) | <0.023 (<0.023, 0.45) | 0.61 |
|
| |||
| IMMUNE PARAMETERS | |||
|
| |||
| Log sCD163 (ng/mL) | 3.0 ± 0.3 | 3.2 ± 0.2 | 0.006 |
| Log sCD14 (ng/mL) | 2.9 ± 0.5 | 3.2 ± 0.4 | 0.02 |
| Log MCP-1 (pg/mL) | 2.3 ± 0.2 | 2.4 ± 0.2 | 0.14 |
| Log CXCL10 (pg/mL) | 2.1 ± 0.3 | 2.4 ± 0.3 | 0.0008 |
|
| |||
|
CARDIAC CT PARAMETERS
| |||
| Any Plaque | 33% (8/24) | 34% (15/44) | 0.95 |
| # Plaque Segments | 0 (0, 2.8) 1.2 ± 2.2 |
0 (0, 2.0) 1.3 ± 2.4 |
0.94 |
| Any Noncalcified Plaque Segments | 13% (3/24) | 32% (14/44) | 0.07 |
| # Noncalcified Plaque Segments | 0 (0, 0) 0.4 ± 1.5 |
0 (0, 1.8) 0.8 ± 1.4 |
0.09 |
| % of Plaque Segments which are Noncalcified | 0 (0, 67) | 75 (50, 100) | 0.03 |
Normally distributed data are presented as means ± SDs or percentages; non-normally distributed data are presented as median (interquartile range). Abbreviations: HTN, hypertension; DM, diabetes mellitus; LDL, low-density lipoprotein; HDL, high-density lipoprotein; SBP, systolic blood pressure; BMI, body mass index; WHR, waist hip ratio; ASCVD, atherosclerotic cardiovascular disease risk score; HCV, hepatitis C virus; ART, antiretroviral therapy; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse-transcriptase inhibitor; PI, protease inhibitor; VL, viral load; FSH, follicle stimulating hormone; AMH antimullerian hormone; MCP-1, monocyte chemoattractant protein-1. P ≤ 0.05 indicates statistical significance.
Missing data on 8 subjects.